GSK Begins Dosing in Late-Stage Trial Evaluating Injectable for Severe Eosinophilic Asthma

GlaxoSmithKline (GSK) has started dosing patients in a phase 3 trial evaluating investigational drug GSK3511294 (GSK’294) for severe eosinophilic asthma (SEA).

GSK’294 is an anti-IL-5 monoclonal antibody meant to be administered via subcutaneous injection every six months, the UK-based drugmaker said, adding that the biologic will be assessed in three phase 3 studies enrolling 2,450 participants.

“Around 10 percent of all asthma patients suffer from the avoidable symptoms of severe eosinophilic asthma and only one in four patients who are eligible for a biologic therapy currently receive one,” said Christopher Corsico, GSK’s senior vice president of development.